LIBOGENE is in the business of cancer molecular diagnosis. The company has established an internationally certified CAP laboratory, and is building a tumor mutant gene databank. LIBOGENE has successfully developed many targeted cancer treatment testing panels and identified novel indigenous tumor resistant gene mutations which can be used as important diagnostic biomarkers.
If you have any questions about our products and services, please input the following details, we will contact you as soon as possible to answer your questions.

繁中  |  简中  |  ENG


Next Generation Sequencing

The Ion Torrent NGS platform used by LIHPAO Life Science is the personal genome machine (PGM) introduced by Life Technologies in 2010. Our R&D department successfully established the use of next generation sequencing (NGS) technology in 2013 as a personal cancer gene accompanying diagnostic platform.

The company developed a targeted drug companion gene diagnosis reagent for colorectal cancer (8 genes), non-small cell lung cancer (16 genes), and comprehensive target drug (30 genes) information genetic diagnostic reagent package. These reagents have been clinically validated.

see work flow SEE FAQ